An interim analysis of real-world safety data from an ongoing, non-interventional, observational study of patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar, in the context of usual care with reference infliximab (Retraction of Vol 13, Pg S 410, 2019)

Bokemeyer B.; Hlavaty T.; Allez M.; Selema P.; Moosavi S.; Cadatal M. J.; Fowler H.; Cheung R.; Lukas M.; Gisbert J. P.

首页> 外文期刊>Journal of Crohn’s & colitis >An interim analysis of real-world safety data from an ongoing, non-interventional, observational study of patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar, in the context of usual care with reference infliximab (Retraction of Vol 13, Pg S 410, 2019)

【24h】

An interim analysis of real-world safety data from an ongoing, non-interventional, observational study of patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar, in the context of usual care with reference infliximab (Retraction of Vol 13, Pg S 410, 2019)

机译：从持续的，非介入性，观察患者的炎症性肠病患者患者的临时分析，CT-P13处理的炎症性肠病患者，incrixImab生物酸，在常规护理中，参考英夫利昔单抗（卷13的收缩， PG S 410,2019）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of Crohn’s & colitis》 |2020年第3期|共1页
作者
Bokemeyer B.; Hlavaty T.; Allez M.; Selema P.; Moosavi S.; Cadatal M. J.; Fowler H.; Cheung R.; Lukas M.; Gisbert J. P.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类杆菌传染病;
关键词

相似文献

外文文献
中文文献

1. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study [J] . Yoo Dae Hyun, Prodanovic Nenad, Jaworski Janusz, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2017,第2期

机译：CT-P13（BioSimilarIngiximab）在类风湿性关节炎患者中的功效和安全性：从Planetra延伸研究中的CT-P13切换到CT-P13的切换与Planetra延伸研究中的持续CT-P13的比较
2. Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and Effectiveness [J] . Cheon Jae Hee, Nah Seongsu, Kang Hyoun Woo, Advances in therapy. . 2021,第8期

机译：英夫利昔单抗BioSimilar CT-P13类风湿性关节炎，炎症性肠疾病和强直性脊柱炎的观测研究：汇总分析长期安全性和有效性
3. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease [J] . María Fernanda Guerra Veloz, Federico Argüelles-Arias, Luisa Castro Laria, World Journal of Gastroenterology . 2018,第46期

机译：在炎症性肠病患者中从原来的英夫利昔单抗改用英夫利昔单抗生物仿制药（CT-P13）的疗效和安全性丧失
4. Extended report: Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study [O] . Dae Hyun Yoo, Nenad Prodanovic, Janusz Jaworski, -1

机译：扩展报告：类风湿关节炎患者中CT-P13（生物仿制药英夫利昔单抗）的疗效和安全性：在PLANETRA扩展研究中从参考英夫利昔单抗转换为CT-P13与持续进行CT-P13之间的比较
5. P590 An interim analysis of real-world safety data from an ongoing, non-interventional, observational study of patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar, in the context of usual care with reference infliximab [O] . B Bokemeyer, T Hlavaty, M Allez, 2019

机译：P590在持续的，非介入性，观察患者的临时分析现实世界安全数据的临时分析，观察患者用CT-P13处理的炎症性肠病患者，incriximab生物酸蛋白，在通常护理的范围内与参考英夫利昔单抗

An interim analysis of real-world safety data from an ongoing, non-interventional, observational study of patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar, in the context of usual care with reference infliximab (Retraction of Vol 13, Pg S 410, 2019)

著录项

相似文献

相关主题

期刊订阅